{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:06Z","timestamp":1793650506818,"version":"4.5.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory abnormalities, including lipids and muscle enzymes, is indicated. A distinguishing feature of JAK inhibitors is a risk for zoster reactivation. Numerically, overall rates of serious infection are similar among JAK inhibitor classes. There are currently no signals for diverticular perforation. VTE incidence rates were similar across comparator groups for the JAK1 selective agents. These observations are not yet conclusive evidence for different safety profiles between JAK1 selective agents and other JAK inhibitors. Differences in study population, design, and concomitant steroid use are examples of potential confounders. It is too early to draw conclusions on long-term outcomes such as malignancy and cardiovascular risk. Post-marketing pharmacovigilance studies will be essential.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa895","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T20:34:00Z","timestamp":1609792440000},"page":"ii24-ii30","source":"Crossref","is-referenced-by-count":132,"title":["The safety of JAK-1 inhibitors"],"prefix":"10.1093","volume":"60","author":[{"given":"Benjamin","family":"Clarke","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5211","authenticated-orcid":false,"given":"Mark","family":"Yates","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Adas","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"2022061217395412000_keaa895-B1","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"2022061217395412000_keaa895-B2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B3","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"2022061217395412000_keaa895-B4","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"The Lancet"},{"key":"2022061217395412000_keaa895-B5","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial","volume":"72","author":"Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2022061217395412000_keaa895-B6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2022061217395412000_keaa895-B7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2022061217395412000_keaa895-B10","doi-asserted-by":"crossref","first-page":"ii34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"2022061217395412000_keaa895-B11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"2022061217395412000_keaa895-B13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"2022061217395412000_keaa895-B14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"2022061217395412000_keaa895-B15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/kex189","article-title":"Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy","volume":"57","author":"Cates","year":"2018","journal-title":"Rheumatology"},{"key":"2022061217395412000_keaa895-B16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"2022061217395412000_keaa895-B17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061217395412000_keaa895-B18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12281-019-00350-w","article-title":"Small-molecule protein kinases inhibitors and the risk of fungal infections","volume":"13","author":"Bechman","year":"2019","journal-title":"Curr Fungal Infect Rep"},{"key":"2022061217395412000_keaa895-B19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"2022061217395412000_keaa895-B20","doi-asserted-by":"crossref","first-page":"e0220178","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis","volume":"14","author":"Castagn\u00e9","year":"2019","journal-title":"PLOS ONE"},{"key":"2022061217395412000_keaa895-B21","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2022061217395412000_keaa895-B22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B23","volume-title":"Baricitinib (olumiant\u25bc): increased risk of diverticulitis, particularly in patients with risk factors","year":"2020"},{"key":"2022061217395412000_keaa895-B24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2022061217395412000_keaa895-B25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/ard.60.5.433","article-title":"Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies","volume":"60","author":"Abu-Shakra","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2022061217395412000_keaa895-B26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood.V87.2.439.bloodjournal872439","article-title":"Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets","volume":"87","author":"Miyakawa","year":"1996","journal-title":"Blood"},{"key":"2022061217395412000_keaa895-B27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2022061217395412000_keaa895-B28","article-title":"Venous thromboembolism risk with JAK inhibitors: A Meta-analysis","author":"Yates","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_2\/ii24\/44029992\/keaa895.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_2\/ii24\/44029992\/keaa895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T17:40:18Z","timestamp":1655055618000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_2\/ii24\/6265536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":28,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa895","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,5,1]]}}}